MetaCap

Avantor (AVTR) vs Bio-Rad Laboratories (BIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Avantor (AVTR) has outperformed Bio-Rad Laboratories (BIO) over the past year, gaining 28.8% versus a gain of 13.3%. Over five years, BIO leads with a -52.2% price change compared with -62.5% for AVTR. Avantor is the larger company by market cap ($10.06 billion vs $9.65 billion), about 1.0 times the size, while Bio-Rad Laboratories is growing revenue faster (+0.7% vs -3.4%).

On valuation, Avantor trades at a lower forward P/E (16.7x vs 36.2x for Bio-Rad Laboratories). Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus -8.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVTR+28.82%BIO+13.32%
+54%+7%-40%
Nov 21, 20251 yearNov 20, 2026
AVTR-62.58%BIO-53.79%
+11%-38%-86%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVTR versus BIO key metrics
MetricAVTRBIO
Share price$14.84$358.90
Market cap$10.06B$9.65B
1-day change-1.85%-2.34%
YTD return+29.49%+18.45%
1-year return+28.82%+13.32%
5-year return-62.54%-52.16%
P/E ratio (TTM)29.689.54
Forward P/E16.7336.23
EPS (TTM)$0.50$37.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.55B$2.58B
Revenue growth (YoY)-3.41%+0.65%
Net income (latest FY)$-530.20M$759.90M
Gross margin32.65%51.87%
Operating margin-3.76%1.83%
Net margin-8.09%29.42%
52-week high$17.45$396.23
52-week low$7.27$236.73
Distance from 52-week high-14.96%-9.42%
Analyst consensusholdhold
Avg. price target upside+16.91%-0.62%
Average volume8.77M257.70K
Shares outstanding677.62M21.83M
Employees13,5007,450
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AVTR has outperformed BIO by 15.5 percentage points over the past year.
  • Avantor trades at a higher earnings multiple (29.7x vs 9.5x trailing P/E).
  • Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus -8.1 cents for Avantor.

About Avantor

AVTR stock →

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.

Industrials · Biotechnology: Laboratory Analytical Instruments · 13,500 employees

About Bio-Rad Laboratories

BIO stock →

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.

Industrials · Biotechnology: Laboratory Analytical Instruments · 7,450 employees

AVTR vs BIO FAQ

Which is bigger, Avantor or Bio-Rad Laboratories?

Avantor (AVTR) is larger, with a market capitalization of $10.06B compared with $9.65B for Bio-Rad Laboratories (BIO).

Which stock has performed better over the past year, AVTR or BIO?

AVTR returned +28.82% over the past 12 months, compared with +13.32% for BIO (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, AVTR or BIO?

BIO has the lower trailing P/E at 9.5, versus 29.7 for AVTR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Avantor and Bio-Rad Laboratories in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons